c-RET

Lenvatinib is a Kinase Inhibitor. The mechanism of action of lenvatinib is as a Receptor …

BT-13 is a selective agonist of glial cell line-derived neurotrophic factor (GDNF) receptor RET independently …

Regorafénib N-oxyde M2 is an active metabolite of Regorafenib. Regorafenib is a multi-target inhibitor for …

Vepafestinib (compound 6) is a RET inhibitor (extracted from patent WO2019039439).

trans-Pralsetinib (trans-BLU-667) is an inhibitor of rearranged during transfection (RET) extracted from patent US20170121312A1 (Compound …

Pz-1 is an inhibitor of VEGFR2 and RET (rearranged during transfection) tyrosine kinase that blocks …

TAS05567 is a potent, highly selective, and ATP-competitive Syk inhibitor (IC50: 0.37 nM). TAS05567 only …

Agerafenib hydrochloride is a highly potent inhibitor of BRAFV600E (Kd: 14 nM).

ENMD-2076 L-(+)-Tartaric acid is the tartaric acid of ENMD-2076, selective activity against Aurora A and …

Danusertib is a small-molecule 3-aminopyrazole derivative with potential antineoplastic activity. Danusertib binds to and inhibits …

Lenvatinib mesylate is an oral and multi-targeted inhibitor of VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, …

Ilorasertib (ABT-348) is an ATP-competitive multitargeted kinase inhibitor, which inhibits Aurora A/Aurora B/Aurora C (IC50s: …

Cabozantinib (XL184) is a potent pan-tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and …

ENMD-2076, a multi-targeted kinase inhibitor, has specific activity against Aurora A, Flt3, KDR/VEGFR2, Flt4/VEGFR3, FGFR1, …

TG101209 is a selective JAK2 inhibitor with IC50 of 6 nM.

SGI-7079 is a new selective Axl inhibitor. SGI-7079 can be a dose-dependent manner inhibited growth …

Treprostinil is a potent DP1, IP and EP2 agonist (EC50: 0.6/1.9/6.2 nM).

RPI-1 is a competitive, potent ATP-dependent Ret kinase inhibitor.

CEP-32496 is a highly potent inhibitor of BRAF.

Regorafenib Hydrochloride is a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine …

Fedratinib (TG101348) is an ATP-competitive inhibitor of JAK2 (IC50: 3 nM) with significantly less potent …

Regorafenib Monohydrate is a novel oral multikinase inhibitor with IC50 values of 13, 4.2, 46, …

Regorafenib (BAY 73-4506) is a multi-targeted receptor tyrosine kinase inhibitor (IC50s: 1.5/2.5/4.2/7/13/22 nM for RET/C-RAF/VEGFR2/c-Kit/VEGFR1/PDGFRβ).

CS-2660, a highly selective, orally available, well tolerated VEGFR2 inhibitor with IC50 of 40 nM, …

PF-477736 is a specifc, effective and ATP-competitive Chk1 inhibitor (Ki: 0.49 nM ) and also …

WHI-P180 is a potent EGFR and Cdk2 inhibitors with IC50 of 4.0 and 1.0 uM, …

ON123300 is a potent and multi-targeted kinase inhibitor for CDK4/Ark5/PDGFRβ/FGFR1/RET/Fyn (IC50: 3.9/5/26/26/9.2/11 nM).

AST 487 is a RET kinase inhibitor, inhibiting RET autophosphorylation and activation of downstream effectors. …

GSK3179106 is RET kinase inhibitor with an IC50 of 0.4 nM

G-749, a new-type FLT3 inhibitor, exhibits effective and sustained inhibition of the FLT3 wild type …

BBT594(NVP-BBT594) is a potent inhibitor of receptor tyrosine kinase RET,Treatment of cancer.

RET V804M-IN-1 is a wt-RET -selective RETV804M kinase inhibitors(IC50 = 20 nM).

Pralsetinib (BLU-667) is a highly potent, selective RET inhibitor (IC50s: 0.4, 0.3, 0.4, 0.4, and …

Selpercatinib is a tyrosine kinase inhibitor with antineoplastic properties(IC50 of 14.0 nM, 24.1 nM, and …

AD80, a multikinase inhibitor, inhibits RET, RAF, SRCand S6K, with greatly reduced mTOR activity.

SPP-86 is an effective and selective cell-permeable inhibitor of RET tyrosine kinase with an IC50 …

Amuvatinib is an orally bioavailable synthetic carbothioamide with potential antineoplastic activity.

TPX-0046 is a RET inhibitor designed to overcome resistance to Selpercatinib and Pralsetinib.